Structural basis for the pathogenicity of parkin catalytic domain mutants
Mutations in the E3 ubiquitin ligase parkin cause a familial form of Parkinson’s disease. Parkin and the mitochondrial kinase PTEN-induced kinase 1 assure quality control of mitochondria through selective autophagy of mitochondria (mitophagy). Whereas numerous parkin mutations have been functionally...
Gespeichert in:
Veröffentlicht in: | The Journal of biological chemistry 2025-01, Vol.301 (1), p.108051, Article 108051 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 1 |
container_start_page | 108051 |
container_title | The Journal of biological chemistry |
container_volume | 301 |
creator | Wagner, Julian P. Sauvé, Véronique Saran, Anshu Gehring, Kalle |
description | Mutations in the E3 ubiquitin ligase parkin cause a familial form of Parkinson’s disease. Parkin and the mitochondrial kinase PTEN-induced kinase 1 assure quality control of mitochondria through selective autophagy of mitochondria (mitophagy). Whereas numerous parkin mutations have been functionally and structurally characterized, several Parkinson’s disease mutations found in the catalytic Rcat domain of parkin remain poorly understood. Here, we characterize two pathogenic Rcat mutants, T415N and P437L. We demonstrate that both mutants exhibit impaired activity using autoubiquitination and ubiquitin vinyl sulfone assays. We determine the minimal ubiquitin-binding segment and show that both mutants display impaired binding of ubiquitin charged on the E2 enzyme. Finally, we use AlphaFold 3 to predict a model of the phospho-parkin:phospho-ubiquitin:ubiquitin-charged E2 complex. The model shows the repressor element of parkin and the N-terminal residues of the catalytic domain form a helix to position ubiquitin for transfer from the E2 to parkin. Our results rationalize the pathogenicity of the parkin mutations and deepen our understanding of the active parkin:E2∼Ub complex. |
doi_str_mv | 10.1016/j.jbc.2024.108051 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3146516862</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0021925824025535</els_id><sourcerecordid>3146516862</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1503-c91735a0e0c9b8fddfad151a5ca71ab2b570b67d624d703745c84d217be069f73</originalsourceid><addsrcrecordid>eNp9kE1LAzEQhoMotlZ_gBfZo5etmWST3cWTFD8KBQ8qeAvZJGuz7kdNskL_vSmtHp3LzLy888I8CF0CngMGftPMm0rNCSZZ3AvM4AhN40BTyuD9GE0xJpCWhBUTdOZ9g2NlJZyiCS05BV7SKVq-BDeqMDrZJpX01if14JKwNslGhvXwYXqrbNgmQx0F92n7RMkg222wKtFDJ6PQjUH2wZ-jk1q23lwc-gy9Pdy_Lp7S1fPjcnG3ShUwTFNVQk6ZxAarsipqrWupgYFkSuYgK1KxHFc815xkOsc0z5gqMk0grwzmZZ3TGbre527c8DUaH0RnvTJtK3szjF5QyDgDXnASrbC3Kjd470wtNs520m0FYLEjKBoRCYodQbEnGG-uDvFj1Rn9d_GLLBpu9wYTn_y2xgmvrOmV0dYZFYQe7D_xPzsqgOw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3146516862</pqid></control><display><type>article</type><title>Structural basis for the pathogenicity of parkin catalytic domain mutants</title><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Wagner, Julian P. ; Sauvé, Véronique ; Saran, Anshu ; Gehring, Kalle</creator><creatorcontrib>Wagner, Julian P. ; Sauvé, Véronique ; Saran, Anshu ; Gehring, Kalle</creatorcontrib><description>Mutations in the E3 ubiquitin ligase parkin cause a familial form of Parkinson’s disease. Parkin and the mitochondrial kinase PTEN-induced kinase 1 assure quality control of mitochondria through selective autophagy of mitochondria (mitophagy). Whereas numerous parkin mutations have been functionally and structurally characterized, several Parkinson’s disease mutations found in the catalytic Rcat domain of parkin remain poorly understood. Here, we characterize two pathogenic Rcat mutants, T415N and P437L. We demonstrate that both mutants exhibit impaired activity using autoubiquitination and ubiquitin vinyl sulfone assays. We determine the minimal ubiquitin-binding segment and show that both mutants display impaired binding of ubiquitin charged on the E2 enzyme. Finally, we use AlphaFold 3 to predict a model of the phospho-parkin:phospho-ubiquitin:ubiquitin-charged E2 complex. The model shows the repressor element of parkin and the N-terminal residues of the catalytic domain form a helix to position ubiquitin for transfer from the E2 to parkin. Our results rationalize the pathogenicity of the parkin mutations and deepen our understanding of the active parkin:E2∼Ub complex.</description><identifier>ISSN: 0021-9258</identifier><identifier>ISSN: 1083-351X</identifier><identifier>EISSN: 1083-351X</identifier><identifier>DOI: 10.1016/j.jbc.2024.108051</identifier><identifier>PMID: 39631693</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>AlphaFold ; E3 ubiquitin ligase ; parkin ; PRKN ; structural biology ; ubiquitin</subject><ispartof>The Journal of biological chemistry, 2025-01, Vol.301 (1), p.108051, Article 108051</ispartof><rights>2024 The Authors</rights><rights>Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c1503-c91735a0e0c9b8fddfad151a5ca71ab2b570b67d624d703745c84d217be069f73</cites><orcidid>0000-0001-6500-1184 ; 0009-0008-8905-1504 ; 0000-0002-5981-4573 ; 0000-0002-1232-4825</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,864,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39631693$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wagner, Julian P.</creatorcontrib><creatorcontrib>Sauvé, Véronique</creatorcontrib><creatorcontrib>Saran, Anshu</creatorcontrib><creatorcontrib>Gehring, Kalle</creatorcontrib><title>Structural basis for the pathogenicity of parkin catalytic domain mutants</title><title>The Journal of biological chemistry</title><addtitle>J Biol Chem</addtitle><description>Mutations in the E3 ubiquitin ligase parkin cause a familial form of Parkinson’s disease. Parkin and the mitochondrial kinase PTEN-induced kinase 1 assure quality control of mitochondria through selective autophagy of mitochondria (mitophagy). Whereas numerous parkin mutations have been functionally and structurally characterized, several Parkinson’s disease mutations found in the catalytic Rcat domain of parkin remain poorly understood. Here, we characterize two pathogenic Rcat mutants, T415N and P437L. We demonstrate that both mutants exhibit impaired activity using autoubiquitination and ubiquitin vinyl sulfone assays. We determine the minimal ubiquitin-binding segment and show that both mutants display impaired binding of ubiquitin charged on the E2 enzyme. Finally, we use AlphaFold 3 to predict a model of the phospho-parkin:phospho-ubiquitin:ubiquitin-charged E2 complex. The model shows the repressor element of parkin and the N-terminal residues of the catalytic domain form a helix to position ubiquitin for transfer from the E2 to parkin. Our results rationalize the pathogenicity of the parkin mutations and deepen our understanding of the active parkin:E2∼Ub complex.</description><subject>AlphaFold</subject><subject>E3 ubiquitin ligase</subject><subject>parkin</subject><subject>PRKN</subject><subject>structural biology</subject><subject>ubiquitin</subject><issn>0021-9258</issn><issn>1083-351X</issn><issn>1083-351X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2025</creationdate><recordtype>article</recordtype><recordid>eNp9kE1LAzEQhoMotlZ_gBfZo5etmWST3cWTFD8KBQ8qeAvZJGuz7kdNskL_vSmtHp3LzLy888I8CF0CngMGftPMm0rNCSZZ3AvM4AhN40BTyuD9GE0xJpCWhBUTdOZ9g2NlJZyiCS05BV7SKVq-BDeqMDrZJpX01if14JKwNslGhvXwYXqrbNgmQx0F92n7RMkg222wKtFDJ6PQjUH2wZ-jk1q23lwc-gy9Pdy_Lp7S1fPjcnG3ShUwTFNVQk6ZxAarsipqrWupgYFkSuYgK1KxHFc815xkOsc0z5gqMk0grwzmZZ3TGbre527c8DUaH0RnvTJtK3szjF5QyDgDXnASrbC3Kjd470wtNs520m0FYLEjKBoRCYodQbEnGG-uDvFj1Rn9d_GLLBpu9wYTn_y2xgmvrOmV0dYZFYQe7D_xPzsqgOw</recordid><startdate>202501</startdate><enddate>202501</enddate><creator>Wagner, Julian P.</creator><creator>Sauvé, Véronique</creator><creator>Saran, Anshu</creator><creator>Gehring, Kalle</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-6500-1184</orcidid><orcidid>https://orcid.org/0009-0008-8905-1504</orcidid><orcidid>https://orcid.org/0000-0002-5981-4573</orcidid><orcidid>https://orcid.org/0000-0002-1232-4825</orcidid></search><sort><creationdate>202501</creationdate><title>Structural basis for the pathogenicity of parkin catalytic domain mutants</title><author>Wagner, Julian P. ; Sauvé, Véronique ; Saran, Anshu ; Gehring, Kalle</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1503-c91735a0e0c9b8fddfad151a5ca71ab2b570b67d624d703745c84d217be069f73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2025</creationdate><topic>AlphaFold</topic><topic>E3 ubiquitin ligase</topic><topic>parkin</topic><topic>PRKN</topic><topic>structural biology</topic><topic>ubiquitin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wagner, Julian P.</creatorcontrib><creatorcontrib>Sauvé, Véronique</creatorcontrib><creatorcontrib>Saran, Anshu</creatorcontrib><creatorcontrib>Gehring, Kalle</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of biological chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wagner, Julian P.</au><au>Sauvé, Véronique</au><au>Saran, Anshu</au><au>Gehring, Kalle</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Structural basis for the pathogenicity of parkin catalytic domain mutants</atitle><jtitle>The Journal of biological chemistry</jtitle><addtitle>J Biol Chem</addtitle><date>2025-01</date><risdate>2025</risdate><volume>301</volume><issue>1</issue><spage>108051</spage><pages>108051-</pages><artnum>108051</artnum><issn>0021-9258</issn><issn>1083-351X</issn><eissn>1083-351X</eissn><abstract>Mutations in the E3 ubiquitin ligase parkin cause a familial form of Parkinson’s disease. Parkin and the mitochondrial kinase PTEN-induced kinase 1 assure quality control of mitochondria through selective autophagy of mitochondria (mitophagy). Whereas numerous parkin mutations have been functionally and structurally characterized, several Parkinson’s disease mutations found in the catalytic Rcat domain of parkin remain poorly understood. Here, we characterize two pathogenic Rcat mutants, T415N and P437L. We demonstrate that both mutants exhibit impaired activity using autoubiquitination and ubiquitin vinyl sulfone assays. We determine the minimal ubiquitin-binding segment and show that both mutants display impaired binding of ubiquitin charged on the E2 enzyme. Finally, we use AlphaFold 3 to predict a model of the phospho-parkin:phospho-ubiquitin:ubiquitin-charged E2 complex. The model shows the repressor element of parkin and the N-terminal residues of the catalytic domain form a helix to position ubiquitin for transfer from the E2 to parkin. Our results rationalize the pathogenicity of the parkin mutations and deepen our understanding of the active parkin:E2∼Ub complex.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>39631693</pmid><doi>10.1016/j.jbc.2024.108051</doi><orcidid>https://orcid.org/0000-0001-6500-1184</orcidid><orcidid>https://orcid.org/0009-0008-8905-1504</orcidid><orcidid>https://orcid.org/0000-0002-5981-4573</orcidid><orcidid>https://orcid.org/0000-0002-1232-4825</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0021-9258 |
ispartof | The Journal of biological chemistry, 2025-01, Vol.301 (1), p.108051, Article 108051 |
issn | 0021-9258 1083-351X 1083-351X |
language | eng |
recordid | cdi_proquest_miscellaneous_3146516862 |
source | DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection |
subjects | AlphaFold E3 ubiquitin ligase parkin PRKN structural biology ubiquitin |
title | Structural basis for the pathogenicity of parkin catalytic domain mutants |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T02%3A50%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Structural%20basis%20for%20the%20pathogenicity%20of%20parkin%20catalytic%20domain%20mutants&rft.jtitle=The%20Journal%20of%20biological%20chemistry&rft.au=Wagner,%20Julian%20P.&rft.date=2025-01&rft.volume=301&rft.issue=1&rft.spage=108051&rft.pages=108051-&rft.artnum=108051&rft.issn=0021-9258&rft.eissn=1083-351X&rft_id=info:doi/10.1016/j.jbc.2024.108051&rft_dat=%3Cproquest_cross%3E3146516862%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3146516862&rft_id=info:pmid/39631693&rft_els_id=S0021925824025535&rfr_iscdi=true |